LncRNAs have been confirmed to regulate gene expression and chromatin structure at epigenetic, transcriptional and post-transcriptional levels, and participate in physiological and pathological processes generally through gene imprinting, histone modification, chromatin remodelling, transcriptional activation, transcriptional interference, alternative splicing and cell cycle control. [11] [12] [13] [14] [15] [16] [17] [18] Increasing studies indicate that numerous lncRNAs, which may function as either oncogenes or tumor suppressor genes, are aberrantly expressed in a variety of human cancers, and contribute to the initiation and progression of malignancies. 19, 20 LncRNAs dysregulation can promote proliferation, invasion and metastasis of tumor cells and inhibit cellular senescence and apoptosis by multiple mechanisms, including working as miRNA sponges, protein scaffolds, regulatory signals or transcript decoys. [21] [22] [23] [24] [25] Notably, lncRNAs may be used as feasible tumor biomarkers and potential therapeutic targets for diagnosis and treatment of cancers due to high tissue specificity and elevated efficiency. 26, 27 Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) is a well-characterized oncogenic regulator among all tumor-associated lncRNAs, and is overexpressed in hepatocellular carcinoma, esophageal squamous cell carcinoma, glioma, osteosarcoma, bladder cancer, colorectal cancer, prostate cancer and B-lymphoblastic leukemia.
The present review summarizes current evidence concerning the expression signature, functional feature, regulatory mechanism and clinical significance of ZEB1-AS1 during the occurrence and development of tumors (Tables 1 and 2 ).
| DISCOVERYANDCHARACTERIZATION OFZEB1-AS1
ZEB1-AS1, which is mainly located in the nucleus, was originally discovered as the most efficient lncRNA to boost cellular proliferation in human HCC by Li EMT, epithelial-mesenchymal transition; ZEB1, zinc finger E-box binding homeobox 1; MLL1, mixed-lineage leukemia 1; BMI1, B cell-specific Moloney murine leukemia virus insertion site 1; CDK2, cyclin dependent kinase 2; MMP2/9, matrix metalloproteinase 2/9; IL-11, interleukin-11; STAT3, signal transducer and activator of transcription 3.
Cancertypes

OverexpressionofZEB1-AS1andclinicalfeatures References
Hepatocellular carcinoma Positive microvascular invasion, shorter overall survival and higher recurrence rate [28] Esophageal squamous cell carcinoma Higher tumor grade, greater depth of invasion, positive lymph node metastasis, poorer overall survival and disease-free survival [36] Prostate cancer Later clinical stage and positive perineural invasion [29] Glioma Advanced clinical stage and reduced overall survival [41] Osteosarcoma Larger tumor size, advanced Enneking stage, positive tumor metastasis, poorer recurrence-free survival and overall survival [44] Bladder cancer Higher histological grade and advanced tumor stage [47] Colorectal cancer Greater depth of tumor invasion, positive microvascular invasion, positive lymph node metastasis, poorer overall survival and lower recurrence-free survival rate [49] B-lymphoblastic leukemia Poorer survival [51] ZEB1-AS1, zinc finger E-box binding homeobox 1 antisense 1.
T A B L E 2 Clinical significance of ZEB1-AS1 in diverse cancers rate is still low due to the high recurrence rate and distant metastasis. 33 Therefore, finding competent biomarkers for early diagnosis and prognosis evaluation will contribute to reduce the mortality of HCC patients.
Li et al 28 
| Esophagealsquamouscellcarcinoma
Esophageal squamous cell carcinoma (ESCC) is the most common category of esophageal cancer, which is the sixth main cause of cancer deaths worldwide, and its incidence rates remain quite high in China. 34 ESCC patients often reach the advanced stage when diagnosed, and the overall 5-year survival rate is less than 10%. 35 The unfavorable prognosis is mainly due to the lake of sensitive and specific indicator for early detection. As a result, the identification of the biomarkers that contribute to early diagnosis of ESCC is extremely meaningful. 
| Prostatecancer
Prostate cancer, which leads to approximately 1-2% of deaths in men annually, is the most commonly diagnosed tumor in males worldwide. 37 The incidence rates of prostate cancer are gradually increasing largely due to the high-fat diet and prolongation of life expectancy. 38 The management of prostate cancer remains a tremendous medical challenge as a result of the lack of efficient therapeutic methods. Thus, elucidating novel molecular mechanisms involved in the development of prostate cancer is an indispensable step to overcome this refractory malignancy.
Su et al 29 reported that ZEB1-AS1 expression levels were significantly enforced in prostate cancer tissues and cell lines compared with those in non-tumor controls. Moreover, upregulated ZEB1-AS1 was remarkably associated with later clinical stage and perineural invasion.
In addition, ZEB1-AS1 knockdown inhibited proliferation and migration of prostate cancer cells. Accordingly, ZEB1-AS1 plays an important role in the initiation and progression of prostate cancer, implying that ZEB1-AS1 may function as a prospective biomarker to improve early diagnosis rate of prostate cancer.
| Glioma
Glioma is the most serious type of primary tumor in central nervous system, and causes exceedingly high death rates each year. 39 Despite considerable improvement in combination treatments including surgical resection, chemotherapy and radiation therapy, the average life expectancy of glioblastoma multiforme, which is the most malignant glioma, is only approximately 15 months. 40 Therefore, identifying new molecular abnormalities concerning glioma progression to establish a specific target is necessary for individual therapeutic strategy of glioma.
Lv et al 41 corroborated that ZEB1-AS1 was highly expressed in glioma tissues compared with that in normal brain tissues, and was also overexpressed in three high-degree glioblastoma cell lines than expression in low-degree glioma cell line. Furthermore, upregulated ZEB1-AS1 was significantly related to clinical stage of glioma and reduced overall survival of glioma patients. In addition, increased ZEB1-AS1 expression was showed as an independent poor prognostic marker for glioma patients by multivariate analysis. Biologically, silencing ZEB1-AS1 dramatically suppressed proliferation, migration and invasion of glioma cells, and promoted cellular apoptosis. In general, ongoing and in-depth exploration for ZEB1-AS1 may make a new breakthrough in the diagnosis and treatment of glioma.
| Osteosarcoma
Osteosarcoma, a highly aggressive cancer, is the most common group of malignant bone tumors in children and adolescents, and occurs nearly 20% lung metastases at the time of original diagnosis. 42 The prognosis of patients with distant metastasis remains extremely poor, and their 5-year survival rate is approximately 20-30%. 43 Hence, exploring appropriate biomarkers for early diagnosis of osteosarcoma is urgently needed. 
| Bladdercancer
Bladder cancer is the ninth most frequent malignancy worldwide,
leading to approximately 52 395 cancer deaths annually. 45 The effectiveness of chemotherapy in advanced bladder cancer is quite limited, and the recurrence rate of bladder cancer remains greatly high. 46 Lin et al 47 
| Colorectalcancer
Colorectal cancer (CRC) is the fourth main cause of tumor-related mortality and the third most commonly diagnosed cancer worldwide. 48 Gong et al 49 demonstrated that ZEB1-AS1 expression was significantly increased in CRC tissues and cell lines compared with that in non-tumor controls, and upregulated ZEB1-AS1 was remarkably correlated with depth of tumor invasion, microvascular invasion and lymph node metastasis. Kaplan-Meier analysis showed that CRC patients with elevated ZEB1-AS1 expression had poorer overall survival and lower recurrence-free survival rate. In addition, silencing ZEB1-AS1 inhibited cellular proliferation and facilitated apoptosis of CRC cells. These data suggest that ZEB1-AS1 is an oncogenic lncRNA in CRC, and is expected to serve as a beneficial molecular marker to predict clinical outcome.
| B-lymphoblasticleukemia
B-lymphoblastic leukemia is one of the most lethal hematological malignancies. 50 Wang et al 51 reported that ZEB1-AS1 was significantly overexpressed in bone marrow tissues of B-lymphoblastic leukemia patients compared with that in healthy controls, and increased 
| REGULATORYMECHANISMSOF ZEB1-AS1
| ZEB1-AS1promotesZEB1expression
ZEB1-AS1 is located in physical contiguity with ZEB1, which is a momentous regulatory factor involved in the EMT. To our knowledge, the antisense transcripts may function as a positive regulator for corresponding gene expression. 52 For example, fibroblast growth factor 
| ZEB1-AS1activatesIL-11/STAT3signalling
The tumor microenvironment is composed of extracellular ma- 
| Otherregulatorymechanisms
DNA methylation is one of the most important epigenetic modifications, and DNA methylation in lncRNAs promoters likely represents an epigenetic modulator of lncRNAs expression. 60 The methylation frequency of ZEB1-AS1 gene is found dramatically decreased during HCC progression, and hypomethylation of ZEB1-AS1 promoter is significantly associated with ZEB1-AS1 overexpression, implying that aberrant methylation of ZEB1-AS1 promoter may exhibit a vital role in ZEB1-AS1 expression and HCC development.
28
Both apoptosis-related proteins (e.g., Bcl-2 and Bax) and cell cycle regulators (e.g., Cyclin D1, CDK2 and p15) play a key role in tumorigenesis and progression. 61 Gong et al 49 
| CONCLUSIONANDFUTURE DIRECTIONS
An increasing number of lncRNAs are found to exert important regulatory functions in gene expression, and the aberrant expression of lncRNAs is gradually recognized as a hallmark feature in cancer. 62 Investigating these molecules as biomarkers or therapeutic targets will be a promising field for cancer treatment. At present, some wellcharacterized lncRNAs have been detected not only in tumor tissues but also in body fluids, such as blood plasma and urine. 63, 64 For instance, both urinary prostate cancer antigen 3 (PCA3) and plasma H19 are regarded as reliable biomarkers in prostate cancer and gastric cancer, respectively. 65, 66 Notably, lncRNA-mediated cis regulation of F I G U R E 1 Model for ZEB1-AS1-activated IL-11/STAT3 signalling in a tumor microenvironment. Upregulated ZEB1-AS1 directly binds to IL-11 protein and facilitates IL-11 protein stability in bone marrow stromal cell of B-lymphoblastic leukemia patients, and subsequently activates STAT3 in B-lymphoblastic leukemia cell in a tumor microenvironment dependent manner to promote cellular proliferation. ZEB1-AS1, zinc finger E-box binding homeobox 1 antisense 1. IL-11, interleukin-11. STAT3, signal transducer and activator of transcription 3 target genes greatly enriches the gene regulatory network of lncRNAs, and exhibits its complexity and diversity. For example, lincRNAp21, a neighboring gene of p21, functions in cis to upregulate p21 expression; and ZEB1-AS1 herein increases ZEB1 expression by cis regulation. 67 The cis regulating mechanism of lncRNAs indicates a viable research direction in this field.
ZEB1-AS1 is identified as an oncogenic lncRNA in diverse malignancies, and upregulated ZEB1-AS1 promotes malignant phenotypes, such as proliferation, invasion and migration by inducing the EMT, activating signalling pathways and regulating cell cycle (Figure 2) . However, the precise molecular mechanisms upstream and downstream of ZEB1-AS1
are not thoroughly understood, and remain to be systematically investigated. ZEB1-AS1 dysregulation is significantly associated with multiple poorer clinicopathological characteristics such as distant metastasis and reduced survival rate, suggesting its potential clinical utility as a favorable biomarker for diagnosis and prognosis. Nevertheless, the expression and function of ZEB1-AS1 in body fluids remains quite obscure, and needs to be further validated. Furthermore, ZEB1-AS1 is extremely prospective to be a feasible drug target due to forceful tumor specificity and reduced systemic toxicity. Despite recent efforts to explore the functions and mechanisms of ZEB1-AS1, its research is still at the preliminary stage. Further systematic studies in larger patient cohorts are warranted to accelerate its clinical application.
F I G U R E 2
Overview for the regulatory mechanisms upstream and downstream of ZEB1-AS1 in cancer progression. The hypomethylation of ZEB1-AS1 promoter upregulates ZEB1-AS1 expression. ZEB1-AS1 increases ZEB1 expression by competitively binding to miR-200s, which directly targets ZEB1. ZEB1-AS1 also enforces ZEB1 expression by recruiting MLL1 or p300 to the promoter region of ZEB1. ZEB1-AS1 induces the EMT by increasing ZEB1, N-cadherin, MMP2, MMP9 and integrin-β1 expression, and decreasing the expression of E-cadherin. ZEB1 inhibits miR200c expression, and miR200c suppresses BMI1 expression, suggesting that ZEB1-AS1/ZEB1/miR200c/BMI1 pathway exhibits a pivotal role in tumor development. ZEB1-AS1 also activates IL-11/STAT3 signalling. In addition, ZEB1-AS1 can impact apoptosis-related proteins (e.g., Bcl-2 and Bax) and cell cycle regulators (e.g., Cyclin D1, CDK2 and p15) to accelerate tumor progression. ZEB1-AS1, zinc finger E-box binding homeobox 1 antisense 1. EMT, epithelial-mesenchymal transition. MLL1, mixed-lineage leukemia 1. BMI1, B cell-specific Moloney murine leukemia virus insertion site 1. CDK2, cyclin dependent kinase 2. MMP2/9, matrix metalloproteinase 2/9. IL-11, interleukin-11. STAT3, signal transducer and activator of transcription 3
